New drug capsule may allow weekly HIV treatment

January 9, 2018, Massachusetts Institute of Technology
HIV infecting a human cell. Credit: NIH

Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule of dosing required for the drug cocktails used to fight the virus, the researchers say.

The new is designed so that patients can take it just once a week, and the drug will release gradually throughout the week. This type of delivery system could not only improve patients' adherence to their treatment schedule but also be used by people at risk of HIV exposure to help prevent them from becoming infected, the researchers say.

"One of the main barriers to treating and preventing HIV is adherence," says Giovanni Traverso, a research affiliate at MIT's Koch Institute for Integrative Cancer Research and a gastroenterologist and biomedical engineer at Brigham and Women's Hospital. "The ability to make doses less frequent stands to improve adherence and make a significant impact at the patient level."

Traverso and Robert Langer, the David H. Koch Institute Professor at MIT, are the senior authors of the study, which appears in the Jan. 9 issue of Nature Communications. MIT postdoc Ameya Kirtane and visiting scholar Omar Abouzid are the lead authors of the paper.

Scientists from Lyndra, a company that was launched to develop this technology, also contributed to the study. Lyndra is now working toward performing a clinical trial using this delivery system.

"We are all very excited about how this new drug-delivery system can potentially help patients with HIV/AIDS, as well as many other diseases," Langer says.

"A pillbox in a capsule"

Although the overall mortality rate of HIV has dropped significantly since the introduction of antiretroviral therapies in the 1990s, there were 2.1 million new HIV infections and 1.2 million HIV-related deaths in 2015.

Several large clinical trials have evaluated whether antiretroviral drugs can prevent HIV infection in healthy populations. These trials have had mixed success, and one major obstacle to preventative treatment is the difficulty in getting people to take the necessary pills every day.

The MIT/BWH team believed that a drug delivery capsule they developed in 2016 might help to address this problem. Their capsule consists of a star-shaped structure with six arms that can be loaded with drugs, folded inward, and encased in a smooth coating. After the capsule is swallowed, the arms unfold and gradually release their cargo.

In a previous study, the researchers found that these capsules could remain in the stomach for up to two weeks, gradually releasing the malaria drug ivermectin. The researchers then set out to adapt the capsule to deliver HIV drugs.

In their original version, the entire star shape was made from one polymer that both provides structural support and carries the drug payload. This made it more difficult to design new capsules that would release drugs at varying rates, because any changes to the polymer composition might disrupt the capsule's structural integrity.

To overcome that, the researchers designed a new version in which the backbone of the star structure is still a strong polymer, but each of the six arms can be filled with a different drug-loaded polymer. This makes it easier to design a capsule that releases drugs at different rates.

"In a way, it's like putting a pillbox in a capsule. Now you have chambers for every day of the week on a single capsule," Traverso says.

Tests in pigs showed that the capsules were able to successfully lodge in the stomach and release three different HIV drugs over one week. The capsules are designed so that after all of the drug is released, the capsules disintegrate into smaller components that can pass through the digestive tract.

Preventing infection

Working with the Institute for Disease Modeling in Bellevue, Washington, the researchers tried to predict how much impact a weekly drug could have on preventing HIV infections. They calculated that going from a daily dose to a weekly dose could improve the efficacy of HIV preventative treatment by approximately 20 percent. When this figure was incorporated into a computer model of HIV transmission in South Africa, the model showed that 200,000 to 800,000 new infections could be prevented over the next 20 years.

"A longer-acting, less invasive oral formulation could be one important part of our future arsenal to stop the HIV/AIDS pandemic," says Anthony Fauci, director of the National Institute of Allergy and Infectious Disease, which partly funded the research.

"Substantial progress has been made to advance , enabling a person living with HIV to achieve a nearly normal lifespan and reducing the risk of acquiring HIV. However, lack of adherence to once-daily therapeutics for infected individuals and pre-exposure prophylaxis (PrEP) for uninfected at-risk people remain a key challenge. New and improved tools for HIV treatment and prevention, along with wider implementation of novel and existing approaches, are needed to end the HIV pandemic as we know it. Studies such as this help us move closer to achieving this goal," Fauci says.

The MIT/BWH team is now working on adapting this technology to other diseases that could benefit from weekly dosing. Because of the way that the researchers designed the polymer arms of the capsule, it is fairly easy to swap different drugs in and out, they say.

"To put other drugs onto the system is significantly easier because the core system remains the same," Kirtane says. "All we need to do is change how slowly or how quickly it will be released."

The researchers are also working on capsules that could stay in the body for much longer periods of time.

Explore further: Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication

More information: Ameya R. Kirtane et al, Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy, Nature Communications (2017). DOI: 10.1038/s41467-017-02294-6

Related Stories

Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication

July 25, 2017
Around half of all medications for chronic diseases are not taken as prescribed, costing the U.S. health care system more than $100 billion in avoidable hospital stays each year.

Ultra-long acting pill offers new hope in eliminating malaria

November 16, 2016
Imagine swallowing a pill today that continues releasing the daily dose of a medicine you need for the next week, month or even longer. Investigators from Brigham and Women's Hospital and their collaborators from the Massachusetts ...

Pill coated with tiny needles can deliver drugs directly into the lining of the digestive tract

October 1, 2014
Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down ...

Fecal microbial transplant by oral capsule noninferior for CDI

November 29, 2017
(HealthDay)—For patients with recurrent Clostridium difficile infection (RCDI), fecal microbial transplantation (FMT) with oral capsules is noninferior to FMT by colonoscopy, according to a study published in the Nov. 28 ...

Recommended for you

HIV-1 viruses transmitted at birth are resistant to antibodies in mother's blood

April 19, 2018
Of the genetically diverse population of HIV-1 viruses present in an infected pregnant woman, the few she might transmit to her child during delivery are resistant to attack by antibodies in her blood, according to new research ...

Top HIV cure research team refutes major recent results on how to identify HIV persistence

April 18, 2018
An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that ...

Scientists discover new way that HIV evades the immune system

April 17, 2018
Scientists have just discovered a new mechanism by which HIV evades the immune system, and which shows precisely how the virus avoids elimination. The new research shows that HIV targets and disables a pathway involving a ...

Team develops new way to fight HIV transmission

April 16, 2018
Scientists at the University of Waterloo have developed a new tool to protect women from HIV infection.

Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus

April 16, 2018
Two genetically modified broadly neutralizing antibodies (bNAbs) protected rhesus macaques from an HIV-like virus, report scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National ...

How does HIV escape cellular booby traps?

April 5, 2018
HIV is believed to have evolved from a simian immunodeficiency virus, or SIV, that originated in chimpanzees. How SIV made the species jump has remained a mystery, since humans possess a defense mechanism that should prevent ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.